Author: Cillian Osterfield - Page 3

IBS and IBD both cause abdominal pain and bowel changes, but only IBD involves inflammation and structural damage. Learn how to tell them apart, what symptoms to watch for, and why proper diagnosis matters.

Pharmacist substitution authority lets pharmacists swap, adjust, or even prescribe medications in many U.S. states. Learn how far this authority goes, which states allow it, and what it means for patient care in 2025.

High-potassium foods can help lower blood pressure-but they can also be dangerous when combined with certain medications. Learn which foods to watch, how meds affect potassium, and how to stay safe.

Generic drug shortages are rising due to low prices, overseas manufacturing dependence, and fragile supply chains. With 270 active shortages in 2025, patients face delayed treatments and rationed care. Solutions require economic reform, not just onshoring.

GLP-1 nausea is common but manageable. Learn how small meals, slow dose increases, ginger, acupressure bands, and timing fluids can help you stick with Ozempic, Wegovy, or Mounjaro without quitting.

Azoles and echinocandins are key antifungal drugs for serious infections. Learn how they work, their safety risks, drug interactions, and when each is preferred-backed by current guidelines and real-world data.

Authorized generics are the exact same medication as brand-name drugs, made in the same factory with identical ingredients. Learn why they're just as effective, how much you can save, and how to ask for them at the pharmacy.

Many antihistamines impair driving ability-even those labeled 'non-drowsy.' Learn which ones are safe, which are dangerous, and how to protect yourself and others on the road.

Anorexia and bulimia are life-threatening mental illnesses with proven treatments. Learn what actually works-Family-Based Treatment, CBT-E, and the barriers keeping people from care.

Tirzepatide (Zepbound) is a dual GLP-1 and GIP agonist that helps with weight loss by targeting appetite, fat storage, and metabolism. It leads to up to 22.4% body weight loss in trials and outperforms older drugs like semaglutide.